Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL, Philadelphia negative).
- Your leukemia must be high-risk, have minimal residual disease, or still have some leukemia cells (5-30% in bone marrow) at transplant time.
- You need a willing stem cell donor (family or unrelated, matched or half-matched).
- You must be between 18 and 65 years old.
- You must be in generally good health (ECOG score 2 or less, few other health problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different ways to manage stem cell transplants in children and young adults with acute lymphoblastic leukemia (ALL). It aims to find the best approach to improve outcomes and reduce complications.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.